Innovation in Drug Research and Development for Prevalent Chronic Diseases Proceedings of a Workshop (2021) / Chapter Skim
Currently Skimming:
5 Learning from Success
5 Learning from Success
Pages 39-50
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 39... ...
If used correctly, these digital health technologies can help streamline health care and make it more effective. (Abdulai)
|
From page 40... ...
Robert Heine, a distinguished Eli Lilly Scholar, called for a new way of thinking about the treatment of chronic diseases, one in which a single drug is used to affect multiple outcomes, with obesity and the metabolic syndrome as a case study. CYSTIC FIBROSIS Coughlin was 30 years old and running for the Massachusetts House of Representatives when he and his wife found out that the 21-weekold fetus his wife was carrying had CF.
|
From page 41... ...
We have drugs that change the course of disease by treating the underlying cause of the disease. We have gene therapy and precision medicine, some gene therapy that is actually curing disease now, and we don't have a health care system that can absorb those upfront costs." The early-stage investment by the Cystic Fibrosis Foundation helped reduce some of the risk for industry to develop much-needed therapies.
|
From page 42... ...
. Other uses of technology in chronic diseases include patient advocacy and com munity building, medical record management, and comorbidity monitoring and management.
|
From page 43... ...
Abdulai offered a case study of a digital technology designed to address an unmet need concerning physical activity in COPD patients, highlighting the role that collaboration among government, academia, industry, and patients can have in bringing treatments and technologies to market. COPD, the third leading cause of death in the United States, is a disease characterized by persistent limitation of airflow in the lungs, with symptoms that include chronic cough, sputum, and shortness of breath.
|
From page 44... ...
. By combining the responses on the questionnaires with the measurements of the digital monitoring devices, the resulting tool makes it possible to better understand the actual disease burden of reduced physical activity and physical functioning in COPD patients, Abdulai said.
|
From page 45... ...
Fatty acids are then stored in and around organs that are not equipped to store them, such as the liver or the heart. This in turn leads to high levels of lipids in the blood and the suite of disorders associated with metabolic syndrome -- hypertension, type 2 diabetes, chronic kidney disease, atherosclerosis, and heart failure.
|
From page 46... ...
46 FIGURE 5-1 Increasing risk with increasing number of metabolic syndrome criteria. SOURCES: Presented by Robert Heine on March 8, 2021, at the Innovation in Drug Research and Development for Prevalent Chronic Diseases workshop; Hess et al., 2017.
|
From page 47... ...
Heine suggested designing and carrying out studies that are focused more on total disease burden than on individual indications. For example, a single patient may be suffering from chronic kidney disease, cardiovascular disease, and diabetes, and clinical trials would ideally examine outcomes relevant to patients with comorbidities.
|
From page 48... ...
2020. Digital health interventions for chronic diseases: A scoping review of evaluation frameworks.
|
From page 49... ...
2017. Increasing mortality from ischaemic heart disease in China from 2004 to 2010: Disproportionate rise in rural areas and elderly subjects.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.